Orgenesis taps industry veteran Mario Philips as company director

CEO Vered Caplan says Philips will help the company pursue collaboration and in-licensing opportunities

Orgenesis - Orgenesis taps industry veteran Mario Philips as company director
The company's point-of-care network reduces the cost and complexity of supplying cell and gene therapies, as well as boosts quality by integrating automated processing units and proprietary technologies

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, said Monday that it appointed industry veteran Mario Philips to the company’s board.

Philips is the boss of France-headquartered PolyNeuroS, which has developed a diagnostic platform technology for neurodegenerative diseases in combination with a therapy to cure motor neuron disease Amyotrophic lateral sclerosis (ALS) and Parkinson’s.

He also acts as strategic partner for the private equity fund, Archimed, and is chairman of the board for its portfolio company, Clean Biologics. In 2017, Philips acted as general manager for Danaher Pall’s biotech business, with full P&L responsibility for a $1.3 billion business unit.

READ: Orgenesis adds UC Davis to its point-of-care network for developing cell, gene therapy products

Philips has board member positions in the life sciences industry with Austar Life Sciences (China), Disposable Lab (France) and Artelis (Belgium). He holds an Engineering degree in Biochemistry from CTL, Gent, and has a postgraduate degree in Marketing from Groep T Leuven.

“Mario brings over 25 years of operational experience and extensive relationships within the life sciences and bioprocessing sectors, which should be invaluable in advancing our point-of-care cell therapy platform and continuing to grow our Contract Development and Manufacturing Organization business,” said Orgenesis CEO Vered Caplan in a statement.

“We believe having such highly respected industry leader will assist us in pursuing collaboration and in-licensing opportunities to speed the development, lower costs and accelerate the path to market for transformative and lifesaving cell and gene therapies,” she added.

Orgenesis Inc, a leading cell and gene therapy enabling company provides centralized contract development and manufacturing organization (CDMO) services through its subsidiary, Masthercell Global. It also offers localized point-of-care development and processing centers to accelerate the development of advanced therapy medicinal products through collaborations and in-licensing with other biopharmaceutical companies.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 


Quick facts: Orgenesis

Price: 7.7 USD

Market: NASDAQ
Market Cap: $169.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...



Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read